The development of a novel dual-targeting peptide vaccine therapy in patients with resected pancreatic cancer.
- Conditions
- resected-pancreatic cancer
- Registration Number
- JPRN-UMIN000007991
- Lead Sponsor
- Wakayama Medical University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Not provided
(1) Interstitial pneumonia or pulmonary fibrosis. (2) Patients who require systemic administration of the following agents during the study treatment period. 1.Corticosteroid 2.Immunosuppresant, Immunostimulant (3) Active infections. (4) Severe complication (heart failure, renal failure, liver failure, bleeding from digestive ulcer, ileus,and uncontrolled diabetes) (5) Pleural effusion, ascites fluid, or pericardial fluid in need of drainage. (6) Active double cancer (include asynchronous double cancer with disease-free duration <=3 year) except carcinoma in situ or intramucosal cancer. (7) Prior treatment of peptide derived from KIF20A, VEGFR-1and VEGFR-2. (8) Prior cancer treatment except for pancreatic cancer (chemotherapy, hormone therapy, antibody therapy, radiation therapy, immunotherapy, and hyperthermia). (9) Severe mental disorder. (10) Sever drug-induced hypersensitivity (11) Unhealed traumatic lesion, including traumatic fracture. (12) History of myocardial infarction, severe unstable angina pectoris, CABG, congestive heart failure, cerebrovascular accident, pulmonary embolism, deep-vein thrombosis, or other severe thromboembolism within 12 months before administration of OCV-C01. (13) Need continuous medication of antiplatelet drug except aspirin. (14) Uncontrolled hypertension. (15) Heart failure and arrhythmia that needs treatment. (16) Aneurysms and varices with serious concern of bleeding. (17) Current participation in other clinical trials. (18) Patients or partners, who don't attempt to doing contraception during the study period (during the study period and until 180 days after the last administration day for male, or until 120 days after the last administration day for female.). (19) Pregnant females or nursing mothers who can not stop lactation during the recruitment until 120 days after the last administration. (20) The subject who was determined by investigator that being not adequate to participate in the trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method